AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider Pierre Thadee Victor Kemula Acquires 10,000 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB) CFO Pierre Kemula bought 10,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was purchased at an average price of $8.59 per share, for a total transaction of $85,900.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $85,900. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

AgomAb Therapeutics Trading Up 4.8%

AGMB stock opened at $9.22 on Friday. The stock has a fifty day moving average of $12.68 and a 200-day moving average of $11.95. AgomAb Therapeutics NV has a fifty-two week low of $7.97 and a fifty-two week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Analysts anticipate that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

Key AgomAb Therapeutics News

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: CEO Tim Jasper Knotnerus purchased 11,000 shares across October 5–6 for approximately $94,380, increasing his ownership substantially. CFO Pierre Kemula also bought 10,000 shares for about $85,900, while director David Epstein acquired 5,000 shares for $43,500. The coordinated insider buying may be viewed as a signal of management and board confidence in AgomAb’s long-term prospects. Insider Buying: AgomAb Therapeutics CEO Purchases Shares
• Positive Sentiment: AgomAb plans to present STENOVA open-label extension data for ontunisertib at UEG Week 2026 and host a scientific symposium focused on fibro-inflammation. The event could provide investors with additional information on the drug’s durability, safety and potential in inflammatory diseases. AgomAb UEG Week 2026 Presentation
• Neutral Sentiment: The planned presentation is a potential near-term catalyst, but the announcement did not include the actual clinical results. Investors will likely await the data before reassessing the program’s prospects.
• Negative Sentiment: AgomAb remains a clinical-stage biotechnology company reporting quarterly losses, with analysts expecting a full-year loss of approximately $1.76 per share. Shares are also trading below their 50-day and 200-day moving averages, reflecting continued volatility and execution risk.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AGMB shares. B. Riley Financial assumed coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. Piper Sandler initiated coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price on the stock. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.